N-nitrosamine risk assessment in pharmaceuticals: Where are we from a regulatory point of view in 2025?
N-nitrosamines have been a concern for decades due to their potential mutagenicity and widespread occurrence across various matrices. While evidence suggests carcinogenicity in animals, their potential carcinogenicity in humans has prompted their initial inclusion in the “cohort of concern” since in...
Saved in:
| Main Authors: | Yue Zhang, Joëlle Widart, Eric Ziemons, Philippe Hubert, Cédric Hubert |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-12-01
|
| Series: | Journal of Pharmaceutical and Biomedical Analysis Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949771X25000350 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
N-nitrosamine Impurities in Medicines: Toxicity, Formation Pathways, Methods of Determination, and Limits (Review)
by: P. P. Shchetinin, et al.
Published: (2020-11-01) -
Analysis and risk assessment of nitrosamines in sartans using GC-MS and Monte Carlo simulation
by: Fatemeh Shomali, et al.
Published: (2025-06-01) -
Design of experiments-assisted UPLC method for quantification of nitrosamine impurities in glimepiride and lobeglitazone sulfate: A green chemistry approach
by: KiranKumar Chagarlamudi, et al.
Published: (2025-06-01) -
Green and sustainable LC-APCI-MS/MS method for simultaneous quantification of genotoxic nitrosamines in antidiabetic medication: sitagliptin
by: Sriram Pepakayala, et al.
Published: (2025-05-01) -
Simultaneous Determination and Quantification of NineNitrosamine Impurities in Semi-Solid Forms Using a GC–MS/MS Method
by: Namjin Lee, et al.
Published: (2025-05-01)